Product Description

RET Monoclonal Antibody

Sizes: 50μl, 100μl

Catalogue Numbers: MB66831-50, MB66831-100

Lead times: 1-2 weeks, if manufacturer has product in stock

Manufacturer/Ship Location: China

Background: The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. By alternative splicing, two isoforms of the Ret proto-oncogene product are generated. The isoforms differ from each other by having either 9 or 51 carboxyterminal amino acids. The Ret gene products include two glycosylated proteins and, in Tunicamycin treated cells, a non-glycosylated protein consistent with the predicted Ret molecμlar weight based on sequence analysis. Tumorspecific rearrangements of the Ret proto-oncogene have been identified in papillary thyroid carcinomas leading to the formation of different transforming fusion proteins sharing the tyrosine kinase domain of Ret. In contrast to the Ret proto-oncogene, the rearranged forms are constitutively phosphorylated on tyrosine and are translocated from the membrane to the cytoplasm.

Category: Primary Antibody

Reactivity: Human

Host: Mouse

Applications: WB, IHC, IF/ICC

Alternate Names: CDHF12, CDHR16, PTC, RET51, Proto-oncogene tyrosine-protein kinase receptor Ret, Cadherin family member 12, Proto-oncogene c-Ret

Clonality: Monoclonal

Conjugate: Unconjugated

Modification: Unmodification

Immunogen: Recombinant fusion protein of human RET. The exact sequence is proprietary.

Dilution: WB (1/500 - 1/5000), IHC (1/50 - 1/200), IF/ICC (1/10 - 1/50)

Specificity: Recognizes endogenous levels of RET protein.

Molecular Weight: ~ 105 kDa

Storage and Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

SwissProt: P07949

Product: Mouse IgM kappa. Supplied in crude ascites with 0.01% sodium azide.

Research Use Only